Compare TG Therapeutics Inc (TGTX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Zimmer Biomet Holdings Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.1× TG Therapeutics Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | ZBH | |
|---|---|---|
Market Cap | $8.26B | $17.36B |
Sector | Health | Health |
52-Week High | $59.06 | $107.71 |
52-Week Low | $26.39 | $79.58 |
Enterprise Value | $8.50B | $24.40B |
Dividend Yield | — | 1.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
